Author

Kyle J. Bednar

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Protocol for the Therapy Personalisation Using Multiomic Analyses in Inflammatory Bowel Disease (THAMES‐IBD) Study

Despite an expanding repertoire of advanced therapies for inflammatory bowel disease (IBD), treatment outcomes remain suboptimal, with only 30%–40% of patients achieving sustained remission. Emerging evidence indicates that therapeutic outcomes are shaped by complex interactions between host immune pathways, the...

John P. Thomas, A. Saifuddin, Sadek Malas et al. · JCC Plus · 0 citations

Oct 2026

Reversal of T1D and Rapid Reduction of β-Cell Stress by IL-10-Dependent MDSCs Induced by TLR4-Ab.

ARTICLE HIGHLIGHTS Therapy with IgG3 Toll-like receptor 4 (TLR4)/myeloid differentiation factor 2 (MD2) agonistic antibody (TLR4-Ab) is a novel approach to type 1 diabetes (T1D) immunotherapy that targets the innate immune system by inducing immunoregulatory myeloid-derived suppressor cells (MDSCs). We sought to define...

Nicolle K. Martin, Luke S. Heuer, Ixchel M. Urbano et al. · Diabetes · 0 citations

Oct 2026

Complementary Ligand Binding Assay and Intact Mass Spectrometry Strategies for Preclinical Pharmacokinetics of Trispecific Antibody Candidates

Multispecific monoclonal antibodies present bioanalytical challenges for pharmacokinetic (PK) assessment because total concentration measurements alone do not resolve molecular integrity, stoichiometry, or product-related heterogeneity. Here, complementary ligand-binding assay (LBA) and intact liquid chromatography–m...

Jake A. Melby, Erik P. Karmele, Iliana Levesque et al. · Journal of the American Soci... · 0 citations